Erythropoietin biosimilar (Zuventus Healthcare)

促红细胞生成素生物类似药 (Zuventus Healthcare)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameErythropoietin biosimilar (Zuventus Healthcare)
Drug Alias Name促红细胞生成素生物仿制药 (Zuventus Healthcare)Eporise
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemia
Global Approved IndicationsAnemia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2012/08/01
Country/TerritoryIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesZuventus Healthcare
China Registration ClassN/A

Develop Information

Active CompaniesZuventus Healthcare
Inactive CompaniesN/A
Active IndicationsAnemia
Inactive IndicationsN/A

Other Information

ATC CodeB03XA01
Related LinksN/A